Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00378768 · ClinicalTrials.gov registry record · Phase 2
Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00378768 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 12 participants.
The verdict
NCT00378768, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies, such as antithymocyte globulin, may stimulate the immune system in different ways and stop cancer cells from growing. PURPOSE: This phase II trial is studying how well antithymocyte globulin works in treating patients undergoing stem cell transplant for multiple myeloma.
Interventions
- BIOLOGICAL anti-thymocyte globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00378768
The ClinicalTrials.gov registry entry for NCT00378768 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which anti-thymocyte globulin is the first listed.
NCT00378768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00378768 about?
NCT00378768 is a clinical study titled "Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma". RATIONALE: Biological therapies, such as antithymocyte globulin, may stimulate the immune system in different ways and stop cancer cells from growing. PURPOSE: This phase II trial is studying how well antithymocyte globulin works in treating patients undergoing stem cell transplant for multiple mye...
What is the current status of trial NCT00378768?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2005-11. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00378768?
The interventions under investigation include: anti-thymocyte globulin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00378768?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.